← Back to Search
Antisense Delivery Using Protamine-oligonucleotide Particles.
M. Junghans, J. Kreuter, A. Zimmer
Published 2000 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Protamine, a polycationic peptide (mol. wt 4000-4500), was evaluated as a potential penetration enhancer for phosphodiester antisense oligonucleotides (ODNs). Unique complexes in the form of nanoparticles were spontaneously formed, which we call 'proticles'. The stability of the particles and the ODNs bound into the proticles was examined in foetal calf serum and cell culture medium. FITC-labelled ODNs bound to protamine showed an increased cellular uptake into human histiocytic lymphoma U 937 cells compared to free ODNs. Proticles significantly decreased cellular growth in a cell proliferation assay using ODNs against the c- myc proto-oncogene.
This paper references
Targeted delivery of antisense oligonucleotides by molecular conjugates
B. Bunnell (1992)
This paper is referenced by
Fluorescence Correlation Spectroscopy for the Characterisation of Drug Delivery Systems
F. Delie (2001)
A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.
Xiaojuan Yang (2011)
Gold nanoparticle coupled with fluorophore for ultrasensitive detection of protamine and heparin.
Jiangna Zhao (2013)
Cell-penetrating peptides; chemical modification, mechanism of uptake and formulation development
Kariem Ezzat (2012)
Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting.
B. Scheicher (2015)
Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine.
Tao Zhang (2010)
The Austrian NANO Initiative: Small Country with Strong Expertise
E. Glenck (2005)
Beyond Cholesterol - New Cardiovascular Biomarkers.
H. Mangge (2016)
Solution Structure and Stability of Tryptophan‐Containing Nucleopeptide Duplexes
I. Gómez-Pinto (2003)
Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction.
G. Mayer (2005)
The inhibitory effects of nanosize delivery system for antisense oligonucleotide of hTERT on EC9706 cells
Z. Zhang (2007)
New protamine quantification method in microtiter plates using o-phthaldialdehyde/N-acetyl-L-cysteine reagent.
D. Lochmann (2004)
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
D. Lochmann (2005)
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.
Y. S. Park (2012)
Anti-inflammatory mediators for molecular imaging of atherosclerosis
Gunter Almer (2014)
Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization
N. A. Hanafy (2020)
Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration
B. Scheicher (2016)
Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors
Lydia Ramzy (2017)
Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films.
Z. Zhang (2008)
Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide.
Y. S. Park (2010)
Effect of size on biological properties of nanoparticles employed in gene delivery
S. Prabha (2016)
Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles.
M. Junghans (2001)
12 – Protamine nanoparticles
Surendra Nimesh (2013)
Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice.
I. Pali-Schöll (2013)
New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo
Tianyang Zhou (2011)
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
G. Almer (2015)
Comparison of antisense oligonucleotide drug delivery systems.
J. Weyermann (2004)
eneration and characterization of a fusion protein of single-chain fragment ariable antibody against hemagglutinin antigen of avian influenza virus and runcated protamine
ao Zhanga (2010)
Analysis of protamine peptides in insulin pharmaceutical formulations by capillary electrophoresis.
C. Lamalle (2016)
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
S. Jin (2007)
THEMED SECTION: VECTOR DESIGN AND DRUG DELIVERY REVIEW Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA
E. Fattal (2009)
Recent advancement of gelatin nanoparticles in drug and vaccine delivery.
N. Sahoo (2015)See more